0000000001246260

AUTHOR

M Rinaldi

showing 4 related works from this author

Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial.

2011

Background: Lactoferrin is a mammalian milk glycoprotein involved in innate immunity. Recent data show that bovine lactoferrin (bLF) prevents late-onset sepsis in preterm very low birth weight (VLBW) neonates. Methods: This is a secondary analysis of data from a multicenter randomized controlled trial where preterm VLBW neonates randomly received bLF (100 mg/day; group A1), bLF + Lactobacillus rhamnosus GG (106 colony-forming units per day; group A2), or placebo (group B) for 6 weeks. Here we analyze the incidence rates of fungal colonization, invasive fungal infection (IFI), and rate of progression from colonization to infection in all groups. Results: This study included 472 neonates who…

fungal sepsisDiseasesInfant Premature DiseasesPediatricsGastroenterologylactoferrin; VLBW neonates; Candida; fungal sepsis; prophylaxisGroup BSettore MED/38 - Pediatria Generale E SpecialisticaAnti-Infective AgentsInfant Very Low Birth WeightCandidabiologyLactoferrinBovine lactoferrin fungal infections very low birth weight newbornsPerinatology and Child Healthlactoferrinprophylaxismedicine.symptomInfant Prematuremedicine.medical_specialtyFungal sepsisPlaceboSepsisLactobacillus rhamnosusIntolerancesInternal medicinemedicineAnimalsHumansfungal sepsiAdverse effectPrematureProphylaxisbusiness.industryVery Low Birth WeightProbioticsInfant NewbornInfantNewbornbiology.organism_classificationmedicine.diseaseLactoferrinLow birth weightMycosesVLBW neonatesPediatrics Perinatology and Child HealthImmunologyCandida; Fungal sepsis; Lactoferrin; Prophylaxis; VLBW neonates; Animals; Anti-Infective Agents; Cattle; Humans; Infant Newborn; Infant Premature; Infant Premature Diseases; Lactoferrin; Mycoses; Probiotics; Infant Very Low Birth Weight; Pediatrics Perinatology and Child Healthbiology.proteinCattlebusiness
researchProduct

Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung ca…

2005

Purpose To study the prognostic value for overall survival of baseline assessment of functional status, comorbidity, and quality of life (QoL) in elderly patients with advanced non—small-cell lung cancer treated with chemotherapy. Patients and Methods Data from 566 patients enrolled onto the phase III randomized Multicenter Italian Lung Cancer in the Elderly Study (MILES) study were analyzed. Functional status was measured as activities of daily living (ADL) and instrumental ADL (IADL). The presence of comorbidity was assessed with a checklist of 33 items; items 29 and 30 of the European Organisation for Research and Treatment of Cancer (EORTC) core questionnaire QLQ-C30 (EORTC QLQ-C30) wer…

MaleCancer Researchmedicine.medical_specialtyLung NeoplasmsActivities of daily livingHealth StatuscarcinomaVinblastineVinorelbineDeoxycytidineolder peopleQuality of lifeInstrumental activitieCarcinoma Non-Small-Cell LungInternal medicineActivities of Daily LivingAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLung cancerAgedAged 80 and overvalidationProportional hazards modelbusiness.industryQLQ-C30Age FactorsCancerVinorelbineclinical trialPrognosismedicine.diseaseGemcitabineComorbidityhumanitiescomorbidityOncologyQuartileQuality of LifePhysical therapyimpactGeriatric oncologyFemalebusinessRandomized-trialmedicine.drug
researchProduct

Work environment, volume of activity and staffing in neonatal intensive care units in Italy: results of the SONAR-nurse study

2016

Background Neonatal units’ volume of activity, and other quantitative and qualitative variables, such as staffing, workload, work environment, care organization and geographical location, may influence the outcome of high risk newborns. Data about the distribution of these variables and their relationships among Italian neonatal units are lacking. Methods Between March 2010-April 2011, 63 neonatal intensive care units adhering to the Italian Neonatal Network participated in the SONAR Nurse study. Their main features and work environment were investigated by questionnaires compiled by the chief and by physicians and nurses of each unit. Twelve cross-sectional monthly-repeated surveys on diff…

Cross-sectional studyStaffingWorkloadCritical Care NursingPediatrics03 medical and health sciences0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaNursing030225 pediatricsIntensive careCritical care nursingSurveys and QuestionnairesNeonatalIntensive Care Units NeonatalMedicineHumansSurveys and Questionnaire030212 general & internal medicineLocationWorkplaceCross-Sectional Studiebusiness.industryResearchNurse-Patient RelationInfant NewbornPatient AcuityInfantWorkloadPatient AcuityPerinatology and Child HealthNewbornInfant Newborn; Intensive Care Units Neonatal; Nurse-Patient Relations; Patient Acuity; Workload; Cross-Sectional Studies; Humans; Infant Newborn; Intensive Care Units Neonatal; Italy; Surveys and Questionnaires; Critical Care Nursing; Pediatric Nursing; Workload; WorkplacePediatric NursingInfant Newborn; Intensive Care Units Neonatal; Nurse-Patient Relations; Patient Acuity; WorkloadIntensive Care UnitsCross-Sectional StudiesItalyWorkforceInfant; Intensive care units; Neonatal; Newborn; Nurse-patient relations; Patient acuity; Workload; Cross-Sectional Studies; Humans; Infant Newborn; Intensive Care Units Neonatal; Italy; Surveys and Questionnaires; Critical Care Nursing; Pediatric Nursing; Workload; Workplace; Pediatrics Perinatology and Child HealthPediatric nursingbusinessNurse-Patient RelationsHuman
researchProduct

Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomized, double blind, placebo controlled, phase III study.

2015

Objective To assess the efficacy of recombinant human erythropoietin (rhEPO) in amyotrophic lateral sclerosis (ALS). Methods Patients with probable laboratory-supported, probable or definite ALS were enrolled by 25 Italian centres and randomly assigned (1:1) to receive intravenous rhEPO 40 000 IU or placebo fortnightly as add-on treatment to riluzole 100 mg daily for 12 months. The primary composite outcome was survival, tracheotomy or >23 h non-invasive ventilation (NIV). Secondary outcomes were ALSFRS-R, slow vital capacity (sVC) and quality of life (ALSAQ-40) decline. Tolerability was evaluated analysing adverse events (AEs) causing withdrawal. The randomisation sequence was computer-…

MaleGastroenterologylaw.inventionRandomized controlled triallaw1506Amyotrophic lateral sclerosisMOTOR NEURON DISEASEeducation.field_of_studyRecombinant ProteinMiddle AgedRecombinant ProteinsTreatment OutcomePsychiatry and Mental HealthNeuromuscularSettore MED/26 - NeurologiaFemaleerythropoietyn clinical trialmedicine.drugHumanALS; MOTOR NEURON DISEASE; Adult; Aged; Amyotrophic Lateral Sclerosis; Double-Blind Method; Erythropoietin; Female; Humans; Male; Middle Aged; Recombinant Proteins; Treatment OutcomeAdultmedicine.medical_specialtyPopulationSocio-culturalePlaceboDouble blindALS; erythropoietyn clinical trialDouble-Blind MethodArts and Humanities (miscellaneous)ALS; MOTOR NEURON DISEASE; Adult; Aged; Amyotrophic Lateral Sclerosis; Double-Blind Method; Epoetin Alfa; Erythropoietin; Female; Humans; Male; Middle Aged; Recombinant Proteins; Treatment Outcome; Neurology (clinical); Psychiatry and Mental Health; Surgery; Arts and Humanities (miscellaneous)Internal medicinemedicineALS; MOTOR NEURON DISEASEHumanseducationErythropoietinAgedbusiness.industryAmyotrophic Lateral SclerosisEpoetin alfamedicine.diseaseSurgeryClinical trialEpoetin AlfaErythropoietinSurgeryNeurology (clinical)ALSbusinessAmyotrophic Lateral Sclerosi
researchProduct